Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for a Phase II study of pembrolizumab and Sylatron in advanced cholangiocarcinoma is displayed, with study details, participant criteria, outcomes, and record history.
    Difference
    53%
    Check dated 2026-11-08T13:47:54.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.2 to v3.8.0 while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:02:03.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A notice about NIH’s transition from the term “artificial intelligence” to “super intelligence” appears above the ClinicalTrials.gov error page.
    Difference
    1%
    Check dated 2026-10-25T14:06:02.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site’s footer revision identifier changed from v3.7.1 to v3.7.2. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T14:35:19.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov revision label in the footer changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T13:45:53.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The 403 Forbidden error view was replaced with the actual study details page for NCT02982720, enabling access to the study information and navigation.
    Difference
    0.5%
    Check dated 2026-09-27T17:35:21.000Z thumbnail image

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.